Statistics for Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial
Total visits
| views | |
|---|---|
| Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial | 1 |
Total visits per month
| views | |
|---|---|
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 0 |
| August 2026 | 0 |
File Visits
| views | |
|---|---|
| 127.pdf | 3 |